New study aims to catch mesothelioma early in High-Risk families

NCT ID NCT04431024

Recruiting now Knowledge-focused Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 6 times

Summary

This study follows 300 adults aged 30 and older who have or may have a BAP1 gene mutation, which raises the risk for mesothelioma and other cancers. Researchers will use advanced CT scans, blood tests, and minimally invasive camera procedures to look for early signs of cancer. Participants visit the NIH once a year for monitoring, and the goal is to learn how to detect mesothelioma earlier in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to better monitoring and earlier diagnosis of mesothelioma in people with BAP1 mutations, potentially improving outcomes.
What could go wrong: This is an observational study, not a treatment trial. It may not directly change care, and the invasive procedures carry risks like infection or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA1-ASSOCIATED PROTEIN-1 (BAP1) MUTATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA1-ASSOCIATED PROTEIN-1 (BAP1) MUTATIONS FAMILIAL CANCER MESOTHELIOMA TUMOR PREDISPOSITION SYNDROME (TPDS)

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.